Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2000-01-25
2001-03-06
Reamer, James H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S673000
Reexamination Certificate
active
06197822
ABSTRACT:
BACKGROUND OF INVENTION
1. Field of the Invention
This invention relates to the use of diphenylacetanilides which selectively bind to mammalian Neuropeptide receptors. It further relates to the use of these compounds and compositions containing these compounds in treating conditions related to an excess of neuropeptide Y such as feeding disorders and certain cardiovascular diseases.
2. Description of the Related Art
Neuropeptide Y, a peptide first isolated in 1982, is widely distributed in the central and peripheral neurons and is responsible for a multitude of biological effects in the brain and the periphery. Various animal studies have shown that activation of neuropeptide Y1 receptors is related to vasoconstriction, Wahlestedt et al
Regul. Peptides,
13: 307-318 (1986), McCauley and Westfall,
J. Pharmacol. Exp. Ther.
261:863-868 (1992), and Grundemar et al
Br. J. Pharmacol.
105:45-50 (1992); and to stimulation of consummatory behavior, Flood and Morley,
Peptides,
10:963-966 (1989), Leibowitz and Alexander,
Peptides,
12:1251-1260 (1991), and Stanley et al
Peptides,.
13:581-587 (1992).
Grundemar and Hakanson
TIPS,
May 1994 [Vol. 15], 153-159, state that, in animals, neuropeptide Y is a powerful stimulus of food intake, and an inducer of vasoconstriction leading to hypertension. They further point out that low levels of neuropeptide Y (NPY) are associated with loss of appetite. These reports clearly indicate that compounds that inhibit the activity of this protein will reduce hypertension and appetite in animals.
EP0759441 and U.S. Pat. No. 5,576,337 report that physiological disorders caused by neuropeptide Y include:
disorders or diseases pertaining to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction, sudden cardiac death, arrhythmia, peripheral vascular disease, and abnormal renal conditions such as impaired flow of fluid, abnormal mass transport, or renal failure; conditions related to increased sympathetic nerve activity for example, during or after coronary artery surgery, and operations and sugery in the gastrointestinal tract;
cerebral diseases and diseases related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, and conditions related to stroke, cerebral vasospasm and hemmorrhage, depression, anxiety, schizophrenia, and dementia;
conditions related to pain or nociception;
diseases related to abnormal gastrointenstinal motility and secretion, such as different forms of ileus, urinary incontinence, and Crohn's disease;
abnormal drink and food intake disorders, such as anorexia and metabolic disorders;
diseases related to sexual dysfunction and reproductive disorders;
conditions or disorders associated with inflammation;
respiratory diseases, such as asthma and conditions related to asthma and bronchoconstriction; and diseases related to abnormal hormone release, such as leutinizing hormone, growth hormone, insulin, and prolactin.
WO 96/14307 refers to substituted benzylamine derivatives which selectively bind to human neuropeptide Y1 receptors.
SUMMARY OF THE INVENTION
This invention comprises a method of inhibiting or alleviating a pathological condition or physiological disorder in a mammal characterized by or associated with neuropeptide Y which comprises administering to a mammal in need of such treatment a neuropeptide Y inhibiting amount of the compound of the formula:
wherein R is —N(C
2
H
5
)
2
or a pharmaceutically acceptable salt thereof
In another aspect, this invention comprises a method of inhibiting or alleviating a pathological condition or physiological disorder in a mammal characterized by or associated with an excess of neuropeptide Y which accompanies administering to a mammal in need of such treatment a neuropeptide Y inhibiting amount of the compound of Formula I shown above.
This invention also comprises a method of treating a pathological condition wherein said pathological condition or physiological disorder is a feeding disorder such as obesity or bulimia.
In another aspect, this invention comprises a method of inhibiting or alleviating a pathological condition or physiological disorder in a mammal wherein said pathological condition or physiological disorder is selected from the group consisting of:
disorders or diseases pertaining to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction, sudden cardiac death, arrhythmia, peripheral vascular disease, and abnormal renal conditions such as impaired flow of fluid, abnormal mass transport, or renal failure;
conditions related to increased sympathetic nerve activity for example, during or after coronary artery surgery, and operations and surgery in the gastrointestinal tract;
cerebral diseases and diseases related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, and conditions related to stroke, cerebral vasospasm and hemorrhage, depression, anxiety, schizophrenia, and dementia;
conditions related to pain or nociception;
diseases related to abnormal gastrointenstinal motility and secretion, such as different forms of ileus, urinary incontinence, and Crohn's disease;
abnormal drink and food intake disorders, such as anorexia and metabolic disorders;
diseases related to sexual dysfunction and reproductive disorders;
conditions or disorders associated with inflammation;
respiratory diseases, such as asthma and conditions related to asthma and bronchoconstriction; and diseases related to abnormal hormone release, such as leutinizing hormone, growth hormone, insulin, and prolactin.
The compound of formula I when R is —N(C
2
H
5
)
2
is basic in nature and capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of the compound of formula I are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, and p-toluenesulfonate.
REFERENCES:
patent: 5576337 (1996-11-01), Bruns, Jr. et al.
patent: 6048900 (2000-04-01), Connell et al.
patent: 0759441 (1997-02-01), None
patent: WO9614307 (1996-05-01), None
Wahlestedt et al,Regul. Peptides, 13: 307-318 (1986).
McCauley and Westfall,J. Pharmacol. Exp. Ther. 261:863-868 (1992).
Grundemar et al,Br. J. Pharmacol. 105:45-50 (1992).
Flood and Morley,Peptides, 12:1251-1260 (1991).
Leibowitz and Alexander,Peptides, 12:1251-1260 (1991).
Stanley et al,Peptides, 13:581-587 (1992).
Grundemar and Hakanson,TIPS, May 1994 [vol. 15], 153-159.
Muramatsu, et al,Tetrahedron LettersNo. 23, pp. 2133-2136 (1973).
Stevens and French,J. Am. Chem. Soc.1953, 75, 657-60.
Hoerhold and Eibish,Tetrahedron 1969, 25, 4277-4286.
Gordon et al,Journal Neurochem. 55:506-513, 1990.
Benson Gregg C.
Brokke Mervin E.
Pfizer Inc.
Reamer James H.
Richardson Peter C.
LandOfFree
Neuropeptide antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuropeptide antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropeptide antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2488761